February 17, 2022 by Chain Drug Review
Lupin Pharmaceuticals, Solosec (secnidazole
Pharmacy, Supplier News
BALTIMORE — Lupin Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years
February 1, 2021 by Chain Drug Review
Lupin Pharmaceuticals, Phil Inc., Solosec (secnidazole
Pharmacy, Supplier News
BALTIMORE — Lupin Pharmaceuticals announced on Monday a partnership with Phil, Inc., which will help deliver cost-effective next-generation access solutions for patients who are prescribed Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec is the only single 2g oral dose therapy for the most common vaginal infection
November 13, 2018 by Chain Drug Review
AstraZeneca’s Pulmicort Respules Inhalation Suspension, budesonide inhalation suspension, Lupin Pharmaceuticals
Pharmacy, Supplier News
MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced that it has received approval for its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules from the United States Food and Drug Administration to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. Lupin’s budesonide inhalation suspension, 0.5
April 23, 2018 by Chain Drug Review
Lupin Pharmaceuticals, Tetrabenazine Tablets, Valeant Pharmaceuticals North America
Pharmacy, Supplier News
MUMBAI, BALTIMORE — Lupin announced today that it has received final approval for its Tetrabenazine tablets, 12.5 mg and 25 mg from the United States Food and Drug Administration (FDA) to market a generic version of Valeant Pharmaceuticals North America’s Xenazine tablets, 12.5 mg and 25 mg. These are used for the treatment of chorea associated
February 22, 2018 by Chain Drug Review
flu medication, generic version of Tamiflu capsules, generic version of Tamiflu oral suspension, Hoffman-La Roche, Lupin Pharmaceuticals, oseltamivir phosphate capsules, oseltamivir phosphate oral suspension
Pharmacy, Supplier News
BALTIMORE — Lupin Pharmaceuticals Inc., the U.S. arm of India-based Lupin Ltd., has received Food and Drug Administration approval for oseltamivir phosphate oral suspension 6 mg (base)/ml, a flu medication. Lupin said its oseltamivir oral suspension product, set to roll out soon, is a generic version of Tamiflu oral suspension (6 mg/ml) from Hoffman-La Roche Inc. Oseltamivir phosphate oral suspension is indicated
May 31, 2017 by Chain Drug Review
Albertsons, Dan Salemi, InspiraChamber, Lupin Pharmaceuticals, Paul McGarty
Leading Headlines, Pharmacy, Supplier News
BALTIMORE — Food and drug retailer Albertsons Cos. has agreed to exclusively provide Lupin Pharmaceuticals Inc.’s InspiraChamber device to asthma and other respiratory patients in its stores. Lupin said Wednesday that Albertsons will offer the InspiraChamber, a valved holding chamber for the enhanced delivery of inhaled aerosol therapies, to patients in its more than 1,700
February 14, 2017 by Chain Drug Review
AAM, Apotex, Association for Accessible Medicines, biosimilars, Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA, GPhA Annual Meeting, Heather Bresch, Jeff Watson, Lupin Pharmaceuticals, mylan, Paul McGarty, Peter Goldschmidt, Sandoz
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly
April 11, 2016 by Chain Drug Review
Gavis, generic version of Intermezzo, Lupin Pharmaceuticals, Purdue Pharma, zolpidem sublingual tablets
Pharmacy, Supplier News
BALTIMORE — Lupin Pharmaceuticals Inc., the U.S. arm of India-based Lupin Ltd., has launched the first product from its Gavis pipeline, zolpidem sublingual tablets 1.75 mg and 3.5 mg, an insomnia drug. Lupin said its product is a generic version of Intermezzo sublingual tablets (1.75 mg and 3.5 mg) from Purdue Pharma. The Lupin generic received
April 20, 2015 by Chain Drug Review and Chain Drug Review
antibiotic, Aurobindo Pharma, cefixime for oral suspension, Lupin Pharmaceuticals, Suprax
Supplier News
DAYTON, N.J. — Aurobindo Pharma Ltd. has received the first Abbreviated New Drug Application approval from the Food and Drug Administration for cefixime for oral suspension, USP, 100 mg/5 ml and 200 mg/5 ml. Cefixime for O.S. is bioequivalent and therapeutically equivalent to Suprax from Lupin Pharmaceuticals Inc. It is indicated for the treatment of